Do we have evidence for policy changes in the treatment of children with latent tuberculosis infection?
Lobato
Mark N
MN
Centers for Disease Control and Prevention, 1600 Clifton Rd, MS E-10, Atlanta, GA 30333, USA.
Jereb
John A
JA
Castro
Kenneth G
KG
D000995:Antitubercular Agents / Q000191:economics / Q000627:therapeutic use*; D002648:Child; D003362:Cost-Benefit Analysis; D004334:Drug Administration Schedule; D016527:Drug Costs / Q000706:statistics & numerical data; D019317:Evidence-Based Medicine / Q000191:economics; D006291:Health Policy / Q000191:economics; D006801:Humans; D007538:Isoniazid / Q000191:economics / Q000627:therapeutic use*; D012293:Rifampin / Q000627:therapeutic use; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics; D014397:Tuberculosis, Pulmonary / Q000175:diagnosis / Q000188:drug therapy* / Q000191:economics
D000995:Antitubercular Agents; D007538:Isoniazid; D012293:Rifampin